두경부 편평상피암용 세포치료 : 파이프라인 분석(2024년)

The Cell Therapies in Head and Neck Squamous Cell Carcinoma - Pipeline Analytics -2024 report published by Mellalta Meets covers the Cell Therapies market opportunity providing Key Competitive Analysis, 17+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports cover pipeline product analysis by stage of development, competitive landscape by phases, companies, clinical trials by regions, cell therapy modalities, and intervention type. Cell Therapies in Head and Neck Squamous Cell Carcinoma-Pipeline Analytics report adds value in terms of describing clinical-stage products for their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

Adoptive cell therapies (ACT) have demonstrated promising outcomes in early-stage trials across various cancers. However, successful approaches in treating HNSCC face specific challenges commonly found in solid tumors. These challenges include the necessity to establish appropriate homing mechanisms for T cells to effectively target the tumor, ensuring adequate T-cell infiltration into the tumor for a robust immune response, and identifying antigens that will not lead to off-tumor effects. While ACT approaches are still in their early stages for HNSCC, there is optimism that they will soon play a significant role in treatment. This may involve potential combinations with checkpoint inhibitors for patients with chemotherapy-refractory disease and potentially in the first-line recurrent metastatic setting.

In this report, Mellalta Meets provides an in-depth analysis of the Cell Therapies in the HNSCC Pipeline covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy areas, investments, and acquisition trends. Currently, there are more than 17 candidates in the Cell Therapies in the HNSCC Pipeline under evaluation in clinical and preclinical studies. The major key players operating in the market are Iovance Biotherapeutics, ImmunityBio, Rapa Therapeutics, TCRCure Biopharma, Immatics, and many more which have a robust clinical pipeline of cell therapy candidates for HNSCC.

As per analysis, the development pipeline is full of different cell therapy modalities like TCR T-cell therapies, tumor-infiltrating lymphocytes (TILs), and combination approaches with immune checkpoint inhibitors (ICI) which can help in addressing HNSCC.

Mellalta's HER2-Low Breast Cancer Pipeline Report - Key Highlights

There are 5 products in the Phase 2 and Phase 1/2 stage of development, representing 15% of the total share of the developing Cell Therapies in HNSCC.

The HNSCC cell therapies landscape is dominated by Phase 1 stage assets accounting for 54.55% followed by Discovery stage products which account for 24.24%.

To be continued...

Report Coverage:

Indication Prioritization: HNSCC market potential

Business Transactions & Strategies: Key collaborations and deal values

HNSCC Cell Therapies Pipeline Development: Product Profiles, Clinical Trials & Results

HNSCC Cell Therapies Acquisition Targets

HNSCC Cell Therapies Competitive Intelligence

Recent and upcoming events

Table of Content

1.Report Overview

2.The Cell Therapies in HNSCC Target Background

• 2.1.Adoptive Cell Therapies in HNSCC
• 2.2.Types of Adoptive Cell Therapies
• 2.3.CAR-T Therapy in HNSCC
• 2.4.CAR-NK cell therapy in HNSCC
• 2.5.TCR T-cell therapy in HNSCC
• 2.6.TIL Therapy in HNSCC

3.Cell Therapies in HNSCC Pipeline Analysis

• 3.1.Development Overview
• 3.2.Pipeline Products by Stage of Development
• 3.3.Cell Therapies in HNSCC Competitive Landscape
• 3.4.Pipeline Products by Company and Region
• 3.5.Type of Cell Therapies in HNSCC Pipeline Landscape

4.Clinical Trials and Research

• 4.1.Cell Therapies Clinical Trials in HNSCC by Region
• 4.2.HNSCC Cell therapies Monotherapy & Combinations Clinical Trials
• 4.3.Clinical & Regulatory Timelines
• 4.4.Late-Stage Profiles Comparisons At-a-glance

5.Licensing, Acquisition, and Collaboration

• 5.1.Cell Therapies in HNSCC Licensing, Acquisition, and Deal Values
• 5.2.Licensing by Transaction Type and Total Amount Size by Phases

6.Pipeline Landscape

• 6.1.Cell Therapies in HNSCC Pipeline Drug Profiles- at a glance
• 6.2.Phase II
  • 6.2.1.LN-145
    • 6.2.1.1.Product Profile
    • 6.2.1.2.Clinical Trial Details
  • 6.2.2.PD-L1 T-haNK
    • 6.2.2.1.Product Profile
    • 6.2.2.2.Clinical Trial Details
• 6.3.Phase I/II
  • 6.3.1.RAPA-201
    • 6.3.1.1.Product Profile
    • 6.3.1.2.Clinical Trial Details
  • 6.3.2.EBV TCR-T
    • 6.3.2.1.Product Profile
    • 6.3.2.2.Clinical Trial Details
  • 6.3.3.IMA402
    • 6.3.3.1.Product Profile
    • 6.3.3.2.Clinical Trial Details
• 6.4.Phase I
  • 6.4.1.HRYZ-T101
    • 6.4.1.1.Product Profile
    • 6.4.1.2.Clinical Trial Details
  • 6.4.2.TSC-200-A0201
    • 6.4.2.1.Product Profile
    • 6.4.2.2.Clinical Trial Details
  • 6.4.3.P-MUC1C-ALLO1
    • 6.4.3.1.Product Profile
    • 6.4.3.2.Clinical Trial Details
  • 6.4.4.NT-175
    • 6.4.4.1.Product Profile
    • 6.4.4.2.Clinical Trial Details
  • 6.4.5.TSC-201-B0702
    • 6.4.5.1.Product Profile
    • 6.4.5.2.Clinical Trial Details
  • 6.4.6.Uzatresgene autoleucel
    • 6.4.6.1.Product Profile
    • 6.4.6.2.Clinical Trial Details
  • 6.4.7.TSC-203-A0201
    • 6.4.7.1.Product Profile
    • 6.4.7.2.Clinical Trial Details
  • 6.4.8.TSC-204-A0201
    • 6.4.8.1.Product Profile
    • 6.4.8.2.Clinical Trial Details
  • 6.4.9.TSC-204-C0702
    • 6.4.9.1.Product Profile
    • 6.4.9.2.Clinical Trial Details
  • 6.4.10.TSC-204-A0101
    • 6.4.10.1.Product Profile
    • 6.4.10.2.Clinical Trial Details
  • 6.4.11.TBio-4101
    • 6.4.11.1.Product Profile
    • 6.4.11.2.Clinical Trial Details
  • 6.4.12.CRTE7A2
    • 6.4.12.1.Product Profile
    • 6.4.12.2.Clinical Trial Details
  • 6.4.13.AGX-148
    • 6.4.13.1.Product Profile
    • 6.4.13.2.Clinical Trial Details
  • 6.4.14.NEXI-003
    • 6.4.14.1.Product Profile
    • 6.4.14.2.Clinical Trial Details
  • 6.4.15.IMA401
    • 6.4.15.1.Product Profile
    • 6.4.15.2.Clinical Trial Details
  • 6.4.16.WU-NK-101
    • 6.4.16.1.Product Profile
    • 6.4.16.2.Clinical Trial Details
  • 6.4.17.IMA203
    • 6.4.17.1.Product Profile
    • 6.4.17.2.Clinical Trial Details
  • 6.4.18.IMA-203CD8
    • 6.4.18.1.Product Profile
    • 6.4.18.2.Clinical Trial Details
• 6.5.Preclinical
  • 6.5.1.ADP-600
  • 6.5.2.IMA204
• 6.6.Discovery
  • 6.6.1.TSC-200-C0702
  • 6.6.2.TSC-201-A0201
  • 6.6.3.TSC-201-A2402
  • 6.6.4.TSC-202-A0201
  • 6.6.5.TSC-203-B0702
  • 6.6.6.TSC-204-A0301
  • 6.6.7.TSC-204-B0702
  • 6.6.8.TSC-203-A2402

7.Cell Therapies in HNSCC SWOT Analysis

8.Appendix

• 8.1.About us